These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28391164)

  • 1. Antibody-based targeting of CD24 enhances antitumor effect of cetuximab via attenuating phosphorylation of Src/STAT3.
    Chen Z; Wang T; Tu X; Xie W; He H; Wang M; Zhang J
    Biomed Pharmacother; 2017 Jun; 90():427-436. PubMed ID: 28391164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD24 controls Src/STAT3 activity in human tumors.
    Bretz NP; Salnikov AV; Perne C; Keller S; Wang X; Mierke CT; Fogel M; Erbe-Hofmann N; Schlange T; Moldenhauer G; Altevogt P
    Cell Mol Life Sci; 2012 Nov; 69(22):3863-79. PubMed ID: 22760497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.
    Ma Z; He H; Sun F; Xu Y; Huang X; Ma Y; Zhao H; Wang Y; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):1929-1940. PubMed ID: 28536738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of Na+/H+ exchanger regulatory factor 2 represses colon cancer progress by suppression of Stat3 and CD24.
    Yoshida M; Zhao L; Grigoryan G; Shim H; He P; Yun CC
    Am J Physiol Gastrointest Liver Physiol; 2016 Apr; 310(8):G586-98. PubMed ID: 26867566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma.
    Chen W; Shen X; Xia X; Xu G; Ma T; Bai X; Liang T
    Liver Int; 2012 Jan; 32(1):70-7. PubMed ID: 22098470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism].
    Zhang J; Ji J; Yuan F; Ma T; Ye ZB; Yu YY; Liu BY; Zhu ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):85-9. PubMed ID: 19538880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
    Fukuoka S; Kojima T; Koga Y; Yamauchi M; Komatsu M; Komatsuzaki R; Sasaki H; Yasunaga M; Matsumura Y; Doi T; Ohtsu A
    Oncotarget; 2017 Feb; 8(7):11020-11029. PubMed ID: 28038457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
    Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging.
    He H; Tu X; Zhang J; Acheampong DO; Ding L; Ma Z; Ren X; Luo C; Chen Z; Wang T; Xie W; Wang M
    Immunobiology; 2015 Dec; 220(12):1328-36. PubMed ID: 26255089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
    Iyer G; Price J; Bourgeois S; Armstrong E; Huang S; Harari PM
    BMC Cancer; 2016 Oct; 16(1):773. PubMed ID: 27716204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
    Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
    Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
    Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
    Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
    Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
    Li R; Yanjiao G; Wubin H; Yue W; Jianhua H; Huachuan Z; Rongjian S; Zhidong L
    Oncotarget; 2017 Mar; 8(12):19354-19364. PubMed ID: 28423613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition.
    Vigneron A; Gamelin E; Coqueret O
    Cancer Res; 2008 Feb; 68(3):815-25. PubMed ID: 18245483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.